Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: A pilot study

Anti-Cancer Drugs

Volumn 7, Issue 7, 1996, Pages 734-737

  Gebbia, Vittorio ^a   Testa, Antonio ^a   Cannata, Giuseppe ^a   Gebbia, Nicola ^a  

^a Institute of Pharmacology   (Italy)

Author keywords

Chemotherapy; Methylprednisolone; Metoclopramide; Ondansetron; Vomiting

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; METHYLPREDNISOLONE; METOCLOPRAMIDE; MITOMYCIN C; NAVELBINE; ONDANSETRON; VINDESINE;

ADULT; AGED; ANTIEMETIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CARCINOMA; FEMALE; HEADACHE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; OVARY CARCINOMA; PRIORITY JOURNAL; PROTECTION; SOMNOLENCE; VOMITING;

EID: 0029966746     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199609000-00003     Document Type: Article

References (13)

1. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995; 6: 805-10.
2. Gebbia V, Cannata G, Testa A, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer 1994; 74: 1945-52.
3. Roila F, Tonato M, Basurto C, et al. Ondansetron. Eur J Cancer 1993; 29A (suppl 1): S16-21.
4. 3 receptor antagonist for the treatment of cancer chemotherapy induced emesis. Eur J Cancer 1993; 29A (suppl 1): S22-9.
5. Kris MG, Tyson LB. Tropisetron (ICS 205-930): a selective 5-hydroxytryptamine antagonist. Eur J Cancer 1993; 29A (suppl 1): S30-2.
6. Navari RM, Madajewicz S, Anderson N, et al. Oral ondanestron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron verus placebo. J Clin Oncol 1995; 13: 2408-16.
7. Gebbia V, Testa A, Valenza R, Cannata G, Tirrito ML, Gebbia N. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. Cancer 1995; 76: 1821-8.
8. Andrews PLR, Davis CJ. The mechanism of emesis induced by anticancer therapies. In: Andrews PRL, Sanger GJ, eds. Emesis in anticancer therapy. London: Chapman & Hall Medical 1993: 113-62.
9. Sanger GJ. The pharmacology of anti-emetic agents. In: Andrews PRL, Sanger GJ, eds. Emesis in anticancer therapy. London: Chapman & Hall Medical 1993: 179-210.
10. Grunberg SM. Potential for combination therapy with the new antiserotoninergic agents. Eur J Cancer 1993; 29A (suppl 1): S39-41.
11. Bregni M, Siene S, DiNicola M, Bonadonna G, Gianni AM. Tropisetron plus holepridol to ameliorate nausea and vomiting associated with high dose alkylating agent cancer chemotherapy. Eur J Cancer 1991; 5: 561-56.
12. Gralla RJ. Nausea and vomiting. In: De Vita, Hellman S, Rosenberg S, eds. Cancer: Principles and practice of oncology. Philadelphia: Lippincott 1989: 2137-44.
13. Kris MG, Gralla RJ, Clark RA, Tyson LB, O'Connell JP, Wertheim MS. Incidence, course, and severity of delayed nausea and vomiting following administration of high-dose cisplatin. J Clin Oncol 1985; 3: 1379-404.